Skip to content
INPLASY
INPLASY

International Platform of Registered Systematic Review and Meta-analysis Protocols

  • Home
  • About us
    • Our History
    • Fees & Services
    • INPLASY registration
    • Platform features
    • INPLASY – reference
    • Our team
    • Become a member
  • Register
  • Log In
  • Browse
  • Submit Now
    • Systematic review
    • Scoping review
    • Methodological studies
    • Update a protocol
    • Update review status
    • Submit with edited file
    • Membership area
  • Resources
    • How to submit
    • How to cite INPLASY
    • Step by step (video)
    • Articles registered on INPLASY.com
    • References
  • Contact Us

INPLASY202230142

Efficacy and safety of brigatinib in ALK-positive non-small cell lung cancer treatment: a systematic review and meta-analysis

Keywords: non-small cell lung cancer; ALK-positive; brigatinib; efficacy; adverse events.

Download PDF - 202230142

Review Status: Completed and published

Copyright © 2020-2024 INPLASYⓇ
Published by INPLASYⓇ